NON-INVASIVE DETERMINATION OF DISEASE ACTIVITY IN CROHN’S DISEASE BY SERUM LUMINEX PROFILING

Gabriella Raffa,Regina Tyree,Kate Carson,Margaret Allaman,Dawn Beaulieu,Robin Dalal,Baldeep Pabla,Elizabeth Scoville,Sara Horst,David Schwartz,Keith Wilson,Lori Coburn

DOI: https://doi.org/10.1093/ibd/izae020.027

2024-01-25

Inflammatory Bowel Diseases

Abstract:Abstract BACKGROUND & AIMS Crohn’s disease (CD) is a chronic inflammatory disease with a complex pathogenesis; treatment and management largely depend on disease activity assessment, which can be challenging and invasive. The aim of this study was to assess the ability of multiplex Luminex technology to identify serum cytokine and/or chemokine markers of disease activity. METHODS Serum samples were prospectively obtained from 103 CD and 40 healthy controls undergoing colonoscopy. CD activity was determined by histologic assessment of colonoscopic biopsies. The Simple Endoscopic Score for Crohn’s Disease (SES) was available for 94 CD patients. We determined if the SES score was predictive of histologic activity (normal, quiescent, mild, moderate, or severe). Patient demographics and clinical history were obtained by chart review. Serum cytokines and chemokines were measured by a 47-plex Luminex assay. Analytes that had more than 70% of values below the lower limit of detection were excluded (GMCSF, IL3, IL17A, IL22, and TNFβ). Analyte profiles in controls v. CD patients were compared using the Mann-Whitney U test with Benjamini-Hochberg (BH) adjustment given multiple comparisons, and by disease activity (control v. inactive v. active) using the Kruskal-Wallis test, with post-hoc Dunn’s test with BH adjustment. RESULTS 34 CD patients were inactive (normal, quiescent) and 69 CD patients had active disease (mild, moderate, severe) on histology. Use of steroids, immunomodulators, and biologics did not differ significantly between the active and inactive CD groups. There was a strong positive correlation between SES score and histologic disease severity (Spearman’s r = 0.58, p<0.001). After BH adjustment, 16 analytes were significantly increased in CD v. controls: Fractalkine, GROα, IFNα2, IL1β, IL4, IL6, IL10, IL13, IL25, IL17F, IL18, MCP3, MCSF, PDGFAA, PDGFABBB, and TGFα. As shown in Table 1, when categorized by disease activity, 4 analytes were significantly increased and one analyte was significantly decreased in inactive disease v. control; 18 analytes were significantly increased in active v. control; and one analyte, CXCL9, which attracts effector T cells to sites of inflammation, was significantly increased in active v. inactive disease. CONCLUSIONS In CD patients, 16 of 42 serum cytokines and chemokines detectable by Luminex assay were increased v. healthy controls. When stratified by histologic disease activity, multiple analytes were found to be increased in inactive or active CD v. controls. Thus, CD is associated with alterations in serum cytokines and chemokines, which was much more frequent in CD patients with histologically active disease. Serum cytokine/chemokine profiling may be a non-invasive strategy to reduce the need for frequent colonoscopy in CD to assess disease activity. Table 1 Serum analyte profiles compared by disease activity (control v. inactive v. active). Data are shown in pg/mL as mean ± SD. p-values are calculated using Kruskal-Wallis test with post-hoc Dunn’s test with BH adjustment for multiple comparisons where 0.05 was considered significant. *p

gastroenterology & hepatology

What problem does this paper attempt to address?

The paper mainly explores two different research topics:

1. **Non-invasive Assessment of Crohn’s Disease (CD) Activity Using Serum Luminex Analysis**:
- **Background and Objective**: Crohn's disease is a complex chronic inflammatory disease, and its treatment and management largely depend on the assessment of disease activity. However, existing assessment methods are often challenging and invasive. Therefore, this study aims to evaluate the feasibility of using multiplex Luminex technology to identify serum cytokine and chemokine markers to determine disease activity.
- **Methods**: Serum samples were prospectively collected from 103 CD patients and 40 healthy controls, and the disease activity status of CD patients was determined by histological examination. The levels of cytokines and chemokines in the serum were measured using a 47-plex Luminex assay, and statistical methods were used to compare differences between different groups.
- **Results**: Among the 103 CD patients, 34 were in an inactive state (normal or quiescent phase), and 69 had varying degrees of active lesions (mild, moderate, or severe). Compared to healthy controls, 16 cytokines and chemokines were significantly elevated in CD patients. Additionally, changes in certain markers were observed between active and inactive phases.
- **Conclusion**: The study indicates that the levels of cytokines and chemokines in the serum of CD patients change, especially in those with histological evidence of active disease. These findings suggest that the serum cytokine/chemokine profile may become a non-invasive strategy to reduce the need for frequent colonoscopies.

2. **Role of P2Y1 Receptor Signaling Pathway in Intestinal Inflammatory Response**:
- **Background and Objective**: Purines are among the most influential and ancient biochemical molecules in evolutionary history. Recent studies have shown that during infection and tissue damage, cells release nucleotides as paracrine signaling molecules to help coordinate host defense and repair responses. These important extracellular signaling molecules activate purinergic receptors, with P2 purinergic receptors playing a crucial role in inflammatory and infectious diseases. However, most current research focuses on purinergic signaling in immune cells and the enteric nervous system, with little known about this process in epithelial cells. This study aims to explore the expression and function of P2 purinergic receptors in intestinal epithelium.
- **Methods**: The Human Protein Atlas database was used to query single-cell RNA sequencing data of the small intestine, colon, and rectum to analyze the expression of P2 purinergic receptors.
- **Preliminary Results**: Computational analysis revealed...

Overall, these two papers explore new biomarkers for assessing Crohn's disease activity and the potential role of the P2Y1 receptor in the intestinal inflammatory process from different perspectives. They are significant for understanding the pathological mechanisms of Crohn's disease and finding new diagnostic and therapeutic methods.